GH Research (NASDAQ:GHRS) Trading Down 0.8% – Here’s What Happened

GH Research PLC (NASDAQ:GHRS) shares were down 0.8% during mid-day trading on Wednesday . The stock traded as low as $8.97 and last traded at $9.03. Approximately 17,495 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 79,145 shares. The stock had previously closed at $9.10.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. JMP Securities restated a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th. Canaccord Genuity Group reduced their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Wednesday, November 20th.

GH Research Stock Performance

The company has a market capitalization of $464.11 million, a PE ratio of -11.43 and a beta of 0.74. The firm’s 50-day simple moving average is $7.93 and its 200 day simple moving average is $10.27.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, equities analysts anticipate that GH Research PLC will post -0.79 earnings per share for the current year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. boosted its holdings in GH Research PLC (NASDAQ:GHRS) by 11.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,251,714 shares of the company’s stock after buying an additional 664,381 shares during the period. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).